期刊文献+

多发性肌炎和皮肌炎合并肺间质病变特点比较分析 被引量:10

Differences in clinical features of interstitial lung disease between polymyositis and dermatomyositis
原文传递
导出
摘要 目的:了解 PM 和 DM 合并肺间质病变(ILD)的临床特点。方法收集并整理114例 PM/DM合并 ILD 患者的临床资料,将其分为 PM-ILD 和 DM-ILD 2组,分析2组患者的一般资料、临床表现、实验室检查、高分辨率 CT(HRCT)、肺功能、血气分析、治疗及转归有无差异,率之间采用四格表χ2检验和 Fisher 确切概率法进行比较。结果 PM/DM-ILD 发病率为35.8%(114/318),DM 较 PM 更易合并 ILD (χ2=5.019,P=0.025)。 PM-ILD 组和 DM-ILD 组在性别构成比上差异有统计学意义(χ2=4.929,P=0.026);DM-ILD 组患者更易出现关节痛/关节炎(χ2=7.756,P=0.005);PM 患者 ILD 更易出现于肌炎之前(χ2=15.555,P=0.01),而 DM 患者 ILD 更易出现于肌炎或皮肤表现之后(χ2=7.002,P=0.008), PM-ILD 组患者更易出现抗 Jo-1抗体阳性(χ2=11.395,P=0.001)。 HRCT 表现上, PM-ILD 组更易出现磨玻璃影(χ^2=7.940, P=0.005)和心包积液(χ2=6.322,P=0.012),DM-ILD 组更易出现斑片影(χ2=5.105,P=0.024);2组患者在肺功能及血气分析上差异无统计学意义;在治疗差异无统计学意义情况下,DM-ILD 组患者的转归明显差于PM-ILD 组(χ^2=7.595,P=0.006)。结论 PM-ILD 和 DM-ILD 患者在性别构成、临床表现、实验室检查、影像学表现和转归上差异有统计学意义,因此推测 PM 和 DM 不同的免疫病理机制导致 PM-ILD 和 DM-ILD 具有不同的临床特点。 Objective To assess if there are differences in clinical features and prognosis of intersti-tial lung disease(ILD) between polymyositis(PM) and dermatomyositis(DM). Methods Medical records of 114 patients with PM/DM(31 PM-ILD, 83 DM-ILD) were reviewed retrospectively to analyze the demograph-ics , clinical manifestations, laboratory findings, high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), blood gas analysis, treatments and prognosis. The differences of measured data were detected by descriptive statisitical analysis, and rates were detected by four-fold table Chi-Square test and Fisher′s exact test. Results The incidence of PM/DM-ILD was 35.8%(114/318) in this study, and DM was more prone to have ILD (χ^2=5.019, P=0.025). There were significant difference in sex ratio between PM-ILD and DM-ILD(χ^2=4.929, P=0.026). Arthralgia/arthritis was more common in DM-ILD than PM-ILD(χ2=7.756, P=0.005). In PM-ILD, ILD was often present before the diagnosis of PM (χ2=15.555, P=0.01),while it was opposite in DM-ILD(χ2=7.002, P=0.008). The frequency of anti-Jo-1 antibody was higher in PM-ILD than in DM-ILD(χ2=11.395, P=0.001). On HRCT, ground-glass opacity(χ2=7.940, P=0.005) and pericardial effu- 〈br〉 sion (χ2=6.322, P=0.012) were more frequently observed in PM-ILD, while patchy shadows were more frequent in DM-ILD (χ2=5.105, P=0.024). There was no difference in PFTs and blood gas analysis between the two groups. With the similar therapeutic regimen, the prognosis of DM-ILD was significantly worse than in PM-ILD (χ2=7.595, P =0.006). Conclusion There are significant differences in sex ratio, clinical manifestations, HRCT imaging findings, and prognosis between PM-ILD and DM-ILD. We propose that the difference in the immunopathological processes of PM and DM leads to different clinical features of ILD between PM and DM.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2014年第10期670-675,共6页 Chinese Journal of Rheumatology
关键词 多发性肌炎 皮肌炎 肺疾病 间质性 Polymyositis Dermatomyositis Lung diseases,interstitial
  • 相关文献

参考文献2

二级参考文献56

  • 1Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44: 1282-1286.
  • 2Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17: 701-706.
  • 3Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.
  • 4Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: review. J Invest Dermatol 1993: 100: S124-S127.
  • 5American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
  • 6Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/ dermatomyositis. Lung 2009; 187:201-206.
  • 7Ye S, Chen XX, Lu XY, Wu ME Deng Y, Huang WQ, et al. Adult clinically amyopathic derrnatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. CIin Rheumatol 2007; 26: 1647-1654.
  • 8Mills ES, Matthews WH. Interstitial pneumonitis in dermatornyositis. JAMA 1956; 160: 1467-1470.
  • 9Made I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-622.
  • 10Chen IJ, Jan Wu Y J, Lin CW, Fan KW, Luo SF, Ho HH, et al. Interstitial lung disease in polymyositis and dermatomyositis.Clin Rheumatol 2009; 28: 639-646.

共引文献54

同被引文献78

  • 1陈瑞林,陶怡.多发性肌炎/皮肌炎134例临床分析[J].广州医学院学报,2006,34(2):29-33. 被引量:8
  • 2Venalis P,Lundberg I E.Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology . 2014
  • 3林玲,姚桂飞,王慧红.皮肌炎合并间质性肺炎8例分析[J].现代中西医结合杂志,2008,17(6):847-848. 被引量:5
  • 4Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis [J]. Lancet, 2003, 362(9388): 971-982.
  • 5Ge Y, Zhou H, Shi J, et al. The efficacy of taerolimus in pa- tients with refractory dermatomyositis/polymyositis: a systematic review[J]. Clin Rheurnatol, 2015, 34(12): 2097-2103. DOI: 10.1007/s 10067 -015 -3065 -0.
  • 6Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series[J]. Rheuma- tology, 2009, 48 (8): 968-971. DOI: 10.1093/rheumatology/ kep157.
  • 7Keir GJ, Maher TM, Hausell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy[J]. Eur Respir J, 2012, 40(3): 641-648. DOI: 10.1183/ 09031936.00163911.
  • 8Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease[J]. Rheumatology, 2015, 54(8): 1420-1428. DOI: 10.1093/rheumatology/kev004.
  • 9Reiff A, Shaham B, Weinberg KI, et al. Anti-CD52 antibody- mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis[J]. J Clin Im-munol, 2011, 31 (4): 615-622. DOI: 10.1007/s10875-011- 9533-7.
  • 10Ruck T, Bittner S, Kuhlmann T, et al. Long-term efficacy of alemtuzumab in polymyositis[J]. Rheumatology, 2015, 54(3): 560-562. DOI : 10.1093/rheumatology/keu484.

引证文献10

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部